Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Corbus Pharmaceuticals Holdings, Inc. Common Stock
Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.
IPO Date: November 1, 2014
Sector: Healthcare
Industry: Biotech
Market Cap: $78.93M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.31 | 3.91%
Avg Daily Range (30 D): $0.32 | 4.87%
Avg Daily Range (90 D): $0.34 | 4.25%
Institutional Daily Volume
Avg Daily Volume: 1.31M
Avg Daily Volume (30 D): .13M
Avg Daily Volume (90 D): .18M
Trade Size
Avg Trade Size (Sh.): 263
Avg Trade Size (Sh.) (30 D): 64
Avg Trade Size (Sh.) (90 D): 68
Institutional Trades
Total Inst.Trades: 430
Avg Inst. Trade: $1.77M
Avg Inst. Trade (30 D): $.78M
Avg Inst. Trade (90 D): $.95M
Avg Inst. Trade Volume: .03M
Avg Inst. Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $2.05M
Avg Closing Trade (30 D): $.78M
Avg Closing Trade (90 D): $.78M
Avg Closing Volume: 39.83K
       
News
Jun 1, 2024 @ 2:00 PM
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targe...
Source: Corbus Pharmaceuticals Holdings, Inc.
May 23, 2024 @ 9:05 PM
Updated Phase 1 Clinical Data for SYS-6002 (CRB-70...
Source: Corbus Pharmaceuticals Holdings, Inc.
May 14, 2024 @ 5:32 PM
Will Pharma And Healthcare Have Competitive Edge I...
Source: Nicolás Jose Rodriguez
Apr 24, 2024 @ 8:05 PM
Corbus Pharmaceuticals Announces Abstract Accepted...
Source: Corbus Pharmaceuticals Holdings, Inc.
Apr 16, 2024 @ 12:50 PM
Here's What Could Help Corbus Pharmaceuticals (CRB...
Source: Zacks Equity Research
Financials
  TTM Q4 2024 FY 2024
Basic EPS $-1.39 $-.76 $-3.68
Diluted EPS $-1.39 $-.76 $-3.68
Revenue $ 1.68M $ 3.55M $ 6.31M
Gross Profit $ $ $
Net Income / Loss $ -16.98M $ -9.53M $ -40.21M
Operating Income / Loss $ -19.78M $ -12.61M $ -48.72M
Cost of Revenue $ $ $
Net Cash Flow $ M $ -2.23M $ 3.47M
PE Ratio    
Splits
Feb 14, 2023:   30:1